Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. T...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2016-10-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/487 |
| _version_ | 1797716535208312832 |
|---|---|
| author | Meysam Seyedifar Farid Abedin Dorkoosh Amir Ali Hamidieh Majid Naderi Hossein Karami Mehran Karimi Masoomeh Fadaiyrayeny Masoumeh Musavi Sanaz Safaei Mohammad Mahdi Ahmadian-Attari Molouk Hadjibabaie Abdol Majid Cheraghali Ali Akbari Sari |
| author_facet | Meysam Seyedifar Farid Abedin Dorkoosh Amir Ali Hamidieh Majid Naderi Hossein Karami Mehran Karimi Masoomeh Fadaiyrayeny Masoumeh Musavi Sanaz Safaei Mohammad Mahdi Ahmadian-Attari Molouk Hadjibabaie Abdol Majid Cheraghali Ali Akbari Sari |
| author_sort | Meysam Seyedifar |
| collection | DOAJ |
| description | Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations.
Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender.
Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males.
Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in.
. |
| first_indexed | 2024-03-12T08:22:53Z |
| format | Article |
| id | doaj.art-9994795ee5484fe08cfd6816f3802aa7 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T08:22:53Z |
| publishDate | 2016-10-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-9994795ee5484fe08cfd6816f3802aa72023-09-02T18:18:20ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072016-10-01104Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in IranMeysam Seyedifar0Farid Abedin Dorkoosh1Amir Ali Hamidieh2Majid Naderi3Hossein Karami4Mehran Karimi5Masoomeh Fadaiyrayeny6Masoumeh Musavi7Sanaz Safaei8Mohammad Mahdi Ahmadian-Attari9Molouk Hadjibabaie10Abdol Majid Cheraghali11Ali Akbari Sari12Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranHematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Pediatrics Hematology-Oncology, Ali-Ebne Abitaleb Hospital Research Center for Children and Adolescent Health [RCCAH], Zahedan University of Medical Sciences, Zahedan, IranThalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, IranHematology Research Center, Shiraz University of Medical Sciences, Shiraz, IranHematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran4Department of Pediatrics Hematology-Oncology, Ali-Ebne Abitaleb Hospital Research Center for Children and Adolescent Health [RCCAH], Zahedan University of Medical Sciences, Zahedan, IranMSc Student of Nursing, Islamic Azad University, Isfahan (Khorasgan) Branch, Isfahan, IranDepartment of Traditional Medicine, Medicinal Plants Research Center of Barij, Kashan, IranResearch Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran. AND Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IranFaculty of Pharmacy, University of Baqiyatallah Medical Sciences, Tehran, IranDepartment of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, IranBackground: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in. .https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/487ThalassemiaQuality of lifeHealth utilityIron chelatorsIran |
| spellingShingle | Meysam Seyedifar Farid Abedin Dorkoosh Amir Ali Hamidieh Majid Naderi Hossein Karami Mehran Karimi Masoomeh Fadaiyrayeny Masoumeh Musavi Sanaz Safaei Mohammad Mahdi Ahmadian-Attari Molouk Hadjibabaie Abdol Majid Cheraghali Ali Akbari Sari Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran International Journal of Hematology-Oncology and Stem Cell Research Thalassemia Quality of life Health utility Iron chelators Iran |
| title | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
| title_full | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
| title_fullStr | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
| title_full_unstemmed | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
| title_short | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
| title_sort | health related quality of life and health utility values in beta thalassemia major patients receiving different types of iron chelators in iran |
| topic | Thalassemia Quality of life Health utility Iron chelators Iran |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/487 |
| work_keys_str_mv | AT meysamseyedifar healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT faridabedindorkoosh healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT amiralihamidieh healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT majidnaderi healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT hosseinkarami healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT mehrankarimi healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT masoomehfadaiyrayeny healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT masoumehmusavi healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT sanazsafaei healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT mohammadmahdiahmadianattari healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT moloukhadjibabaie healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT abdolmajidcheraghali healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT aliakbarisari healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran |